Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularizatio
Phase 1
Recruiting
- Conditions
- choroidal neovascularization diabetic retinopathy retinal vein occulusion neovascular glaucoma retinopathy of prematurity central serous chorioretinopathy
- Registration Number
- JPRN-UMIN000011094
- Lead Sponsor
- Kobe University Graduate school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 510
Inclusion Criteria
Not provided
Exclusion Criteria
1)high risk of stroke or myocardial infarction 2)systemic diseases with vessel occulusions 3)ocular infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the visual acuity at 12 months from the initial treatment
- Secondary Outcome Measures
Name Time Method The number of injections required over 12 months of follow-up. The presence or absence of complications.